GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius AG (STU:SRT) » Definitions » Institutional Ownership

Sartorius AG (STU:SRT) Institutional Ownership : 0.52% (As of May. 23, 2024)


View and export this data going back to . Start your Free Trial

What is Sartorius AG Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Sartorius AG's institutional ownership is 0.52%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Sartorius AG's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Sartorius AG's Float Percentage Of Total Shares Outstanding is 0.00%.


Sartorius AG Institutional Ownership Historical Data

The historical data trend for Sartorius AG's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius AG Institutional Ownership Chart

Sartorius AG Historical Data

The historical data trend for Sartorius AG can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 0.53 0.54 0.52 0.47 0.52 0.53 0.51 0.51 0.51 0.52

Sartorius AG Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Sartorius AG (STU:SRT) Business Description

Address
Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079
Sartorius AG is a leading provider of bioprocessing solutions. Its Bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology, or SUT. Its Lab Products and Services division offers a wide range of products for lab use, including scales, pipettes, and filtration equipment. As of 2022, the Bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 74% ownership and 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (37% of 2022 sales), the Americas (37%), and Asia-Pacific (26%). We estimate China revenue to be around 10%.